Home › Kanser sa Tiyan › Georgia › Atlanta
Pag-aaral pangklinika para sa Kanser sa Tiyan sa Atlanta, GA
14 pag-aaral para sa Kanser sa Tiyan ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Atlanta (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Atlanta VA Medical Center, Decatur · 6 mi ang layo
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- Emory Winship Cancer Institute, Atlanta
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Nagre-recruitPhase 2/3
- Emory University, Atlanta
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Nagre-recruitPhase 3
- Research Site, Atlanta
- Research Site, Atlanta
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Nagre-recruitPhase 1/2
- Emory University, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
- Winship Cancer Institute - Emory University, Atlanta
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Emory University, Atlanta
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Winship Cancer Center - Emory University, Atlanta
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- Winship Cancer Institute / Emory University, Atlanta
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Nagre-recruitPhase 1/2
- Emory University, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Atlanta
A Beta-only IL-2 ImmunoTherapY Study
Nagre-recruitPhase 1/2
- Emory - Winship Cancer Institute, Atlanta
Pag-aaral para sa Kanser sa Tiyan sa ibang lungsod
- Houston, TX42 pag-aaral
- Boston, MA32 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN28 pag-aaral
- Baldwin Park, CA22 pag-aaral
- Los Angeles, CA22 pag-aaral
- Arlington, VA20 pag-aaral
- Dallas, TX19 pag-aaral
- San Antonio, TX19 pag-aaral
- St. Louis, MO18 pag-aaral
- Grand Rapids, MI18 pag-aaral
- Washington, DC16 pag-aaral
Iba pang pag-aaral sa Atlanta
- Kanser (lahat ng uri)49 pag-aaral
- Non-Small Cell Lung Cancer47 pag-aaral
- Multiple Myeloma42 pag-aaral
- Kanser sa Suso41 pag-aaral
- Kanser sa Prostate33 pag-aaral
- Acute Myeloid Leukemia31 pag-aaral
- Kanser sa Ovary29 pag-aaral
- Colorectal Cancer29 pag-aaral
- Kanser sa Baga29 pag-aaral
- Metastatic Cancer28 pag-aaral
- Major Depressive Disorder25 pag-aaral
- Pagkabigo ng Puso25 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.